SCHEMBL3697968

SCHEMBL3697968

CC(C)(C)OC(=O)NC(Cc1ccc(-c2cccc(Cl)c2)cc1)c1nnn[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.45
MMEL1 Q495T6 4/20 0.44
ALDH1A1 P00352 4/20 0.44
PTPRB P23467 3/20 0.44
CTSS P25774 2/20 0.43
CTSK P43235 2/20 0.43
MME P08473 3/20 0.42
LMNA P02545 3/20 0.42
PKM P14618 3/20 0.42
HPGD P15428 3/20 0.42
HTT P42858 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
AGTR1 P30556 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3697969 1.00 CTSL (0.45) CTSLMMEL1ALDH1A1PTPRBCTSS
SCHEMBL3696928 0.90 NPSR1 (0.50) ALDH1A1PTPRBCTSSCTSKMME
SCHEMBL3693514 0.89 CTSS (0.53) CTSLALDH1A1PTPRBCTSSCTSK
SCHEMBL3693517 0.89 CTSS (0.53) CTSLALDH1A1PTPRBCTSSCTSK
SCHEMBL6791477 0.83 ALDH1A1 (0.58) CTSLALDH1A1PTPRBCTSSCTSK
SCHEMBL1768317 0.79 CTSL (0.60) CTSLMMEL1CTSSCTSKMME
SCHEMBL1768318 0.79 CTSL (0.60) CTSLMMEL1CTSSCTSKMME
SCHEMBL2878542 0.79 CTSL (0.60) CTSLMMEL1CTSSCTSKMME
SCHEMBL1912548 0.78 MME (0.52) CTSLMMEL1CTSSCTSKMME
SCHEMBL1912623 0.77 CTSL (0.50) CTSLMMEL1CTSSCTSKMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877815-B2 Substituted carbamoylcycloalkyl acetic acid derivatives as NEP NOVARTIS AG (CH) 2014-11-04 US disclosed
EP-2640689-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS Novartis AG (CH) 2013-09-25 EP disclosed
WO-2012065953-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2012-05-24 WO disclosed
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP NOVARTIS AG (CH) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122764-A1 SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP MME, REN, ECE1 CTSL 451/4885MMEL1 1000/4885ALDH1A1 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.